CN104837826B - 制备用于治疗癌症的化合物的新型方法 - Google Patents
制备用于治疗癌症的化合物的新型方法 Download PDFInfo
- Publication number
- CN104837826B CN104837826B CN201380064338.7A CN201380064338A CN104837826B CN 104837826 B CN104837826 B CN 104837826B CN 201380064338 A CN201380064338 A CN 201380064338A CN 104837826 B CN104837826 B CN 104837826B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- group
- reacting
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C(CC=CC(F)=C1C*2CC2)=C1F)=** Chemical compound CC(C(CC=CC(F)=C1C*2CC2)=C1F)=** 0.000 description 12
- DRBOJCULJIZLGA-MSOLQXFVSA-N CC(C)(C)OC(N(C1)CC1([C@H](CCCC1)N1[C@H](CO)c1ccccc1)O)=O Chemical compound CC(C)(C)OC(N(C1)CC1([C@H](CCCC1)N1[C@H](CO)c1ccccc1)O)=O DRBOJCULJIZLGA-MSOLQXFVSA-N 0.000 description 1
- SFNQXXOXVNHSEP-HUUCEWRRSA-N CC([C@@H](CCCC1)N1[C@H](CO)c1ccccc1)=N Chemical compound CC([C@@H](CCCC1)N1[C@H](CO)c1ccccc1)=N SFNQXXOXVNHSEP-HUUCEWRRSA-N 0.000 description 1
- ZNWIKIUSBKGGQD-OMKBGSMGSA-N CN(C1)CC1([C@H](CCCCCC1)C1[C@H](CO)c1ccccc1)O Chemical compound CN(C1)CC1([C@H](CCCCCC1)C1[C@H](CO)c1ccccc1)O ZNWIKIUSBKGGQD-OMKBGSMGSA-N 0.000 description 1
- OYFXNHQMVVKMKO-ZENAZSQFSA-N Cc(cc1[F]C(CCC2)N[C@@H]2C(C2)(CN2C(c(ccc(F)c2F)c2F)=O)O)ccc1N Chemical compound Cc(cc1[F]C(CCC2)N[C@@H]2C(C2)(CN2C(c(ccc(F)c2F)c2F)=O)O)ccc1N OYFXNHQMVVKMKO-ZENAZSQFSA-N 0.000 description 1
- NXRQXCFBZGIRGN-UHFFFAOYSA-N O=C(c(ccc(F)c1F)c1F)Cl Chemical compound O=C(c(ccc(F)c1F)c1F)Cl NXRQXCFBZGIRGN-UHFFFAOYSA-N 0.000 description 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N OC(C1)(CN1C(c(ccc(F)c1F)c1Nc(ccc(I)c1)c1F)=O)[C@H]1NCCCC1 Chemical compound OC(C1)(CN1C(c(ccc(F)c1F)c1Nc(ccc(I)c1)c1F)=O)[C@H]1NCCCC1 BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 1
- VUDHGWCDCCOMSU-BUGOSIMFSA-N OC[C@H](c1ccccc1)N(CCCC1)[C@@H]1C(C1)(CN1C(C(C1F)C=CC(F)=C1F)=O)O Chemical compound OC[C@H](c1ccccc1)N(CCCC1)[C@@H]1C(C1)(CN1C(C(C1F)C=CC(F)=C1F)=O)O VUDHGWCDCCOMSU-BUGOSIMFSA-N 0.000 description 1
- ILSCRNPCQIFVHY-CABCVRRESA-N OC[C@H](c1ccccc1)N(CCCC1)[C@@H]1C1(CNC1)O Chemical compound OC[C@H](c1ccccc1)N(CCCC1)[C@@H]1C1(CNC1)O ILSCRNPCQIFVHY-CABCVRRESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810758236.XA CN108948043B (zh) | 2012-10-12 | 2013-10-14 | 制备用于治疗癌症的化合物的新型方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713104P | 2012-10-12 | 2012-10-12 | |
| US61/713,104 | 2012-10-12 | ||
| PCT/US2013/064866 WO2014059422A1 (en) | 2012-10-12 | 2013-10-14 | Novel process for making compounds for use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810758236.XA Division CN108948043B (zh) | 2012-10-12 | 2013-10-14 | 制备用于治疗癌症的化合物的新型方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104837826A CN104837826A (zh) | 2015-08-12 |
| CN104837826B true CN104837826B (zh) | 2018-07-27 |
Family
ID=49474740
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810758236.XA Active CN108948043B (zh) | 2012-10-12 | 2013-10-14 | 制备用于治疗癌症的化合物的新型方法 |
| CN201380064338.7A Active CN104837826B (zh) | 2012-10-12 | 2013-10-14 | 制备用于治疗癌症的化合物的新型方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810758236.XA Active CN108948043B (zh) | 2012-10-12 | 2013-10-14 | 制备用于治疗癌症的化合物的新型方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9771347B2 (enExample) |
| EP (1) | EP2909188B1 (enExample) |
| JP (2) | JP6300042B2 (enExample) |
| KR (1) | KR102204520B1 (enExample) |
| CN (2) | CN108948043B (enExample) |
| AU (1) | AU2013328929B2 (enExample) |
| BR (1) | BR112015008113B1 (enExample) |
| CA (1) | CA2889466C (enExample) |
| CL (1) | CL2015000926A1 (enExample) |
| CR (2) | CR20200237A (enExample) |
| EA (1) | EA030613B1 (enExample) |
| ES (1) | ES2671502T3 (enExample) |
| GE (1) | GEP201706690B (enExample) |
| HK (1) | HK1213567A1 (enExample) |
| HR (1) | HRP20180670T1 (enExample) |
| IL (1) | IL238116B (enExample) |
| IN (1) | IN2015DN03928A (enExample) |
| MA (1) | MA38085B1 (enExample) |
| MX (2) | MX372708B (enExample) |
| MY (1) | MY186549A (enExample) |
| NZ (1) | NZ706723A (enExample) |
| PE (3) | PE20191818A1 (enExample) |
| PH (1) | PH12015500785B1 (enExample) |
| PL (1) | PL2909188T3 (enExample) |
| SA (1) | SA515360271B1 (enExample) |
| SG (1) | SG11201502795VA (enExample) |
| SI (1) | SI2909188T1 (enExample) |
| TR (1) | TR201807861T4 (enExample) |
| UA (1) | UA115455C2 (enExample) |
| WO (1) | WO2014059422A1 (enExample) |
| ZA (1) | ZA201502349B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6300042B2 (ja) | 2012-10-12 | 2018-03-28 | エグゼリクシス， インコーポレイテッド | 癌の処置に使用するための化合物の製造方法 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| EP3881833B1 (en) | 2015-06-30 | 2023-11-01 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
| BR112019002036A2 (pt) | 2016-08-12 | 2019-05-14 | Genentech Inc | métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal |
| CN109862917A (zh) | 2016-09-29 | 2019-06-07 | 基因泰克公司 | Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法 |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| US20240173329A1 (en) | 2021-03-09 | 2024-05-30 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| US20240366609A1 (en) | 2021-04-06 | 2024-11-07 | Genentech, Inc. | Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365676A (zh) * | 2005-10-07 | 2009-02-11 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
| CN101605540A (zh) * | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1563587A (en) * | 1924-09-20 | 1925-12-01 | Raney Murray | Method of preparing catalytic material |
| US1628190A (en) * | 1926-05-14 | 1927-05-10 | Raney Murray | Method of producing finely-divided nickel |
| US1915473A (en) * | 1930-12-31 | 1933-06-27 | Raney Murray | Method of preparing catalytic material |
| US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| AU685933B2 (en) | 1994-04-01 | 1998-01-29 | Shionogi & Co., Ltd. | Oxime derivative and bactericide containing the same as active ingredient |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| WO1998037881A1 (en) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| IL132840A (en) | 1997-07-01 | 2004-12-15 | Warner Lambert Co | Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors |
| NZ501277A (en) | 1997-07-01 | 2002-12-20 | Warner Lambert Co | -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
| WO2000035435A1 (en) | 1998-12-15 | 2000-06-22 | Warner-Lambert Company | Use of a mek inhibitor for preventing transplant rejection |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| ES2253928T3 (es) | 1998-12-22 | 2006-06-01 | Warner-Lambert Company Llc | Quimioterapia de combinacion que comprende un inhibidor mitotico y un inhibidor mek. |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| IL144103A0 (en) | 1999-01-07 | 2002-05-23 | Warner Lambert Co | Antiviral method using mek inhibitors |
| EP1140062B1 (en) | 1999-01-07 | 2005-04-06 | Warner-Lambert Company LLC | Treatment of asthma with mek inhibitors |
| AU2482700A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
| WO2000041505A2 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Anthranilic acid derivatives |
| AU2201500A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| HRP20010524A2 (en) | 1999-01-13 | 2002-08-31 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| CA2377092A1 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| KR20020015379A (ko) | 1999-07-16 | 2002-02-27 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 엠이케이 억제제를 사용하는 만성 동통의 치료방법 |
| CN1365277A (zh) | 1999-07-16 | 2002-08-21 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| CN1373660A (zh) | 1999-07-16 | 2002-10-09 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| ES2316383T3 (es) | 1999-09-17 | 2009-04-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| CA2403017A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| CA2416685C (en) | 2000-07-19 | 2008-10-07 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| JP2004507518A (ja) * | 2000-08-25 | 2004-03-11 | ワーナー−ランバート・カンパニー・エルエルシー | Ｎ−アリール−アントラニル酸及びその誘導体の製造法 |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
| US7085492B2 (en) | 2001-08-27 | 2006-08-01 | Ibsen Photonics A/S | Wavelength division multiplexed device |
| CA2460118A1 (en) | 2001-10-31 | 2003-05-08 | Pfizer Products Inc. | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome |
| DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
| JP2005515253A (ja) | 2002-01-23 | 2005-05-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル |
| RU2300528C2 (ru) | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек |
| DE60330227D1 (de) | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2003103590A2 (en) | 2002-06-11 | 2003-12-18 | Merck & Co., Inc. | (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| AU2003248813A1 (en) | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| JP4617299B2 (ja) | 2003-03-03 | 2011-01-19 | アレイ バイオファーマ、インコーポレイテッド | ｐ３８阻害剤及びその使用法 |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| EP1641804A1 (en) | 2003-06-20 | 2006-04-05 | Celltech R & D Limited | Thienopyridone derivatives as kinase inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| EP1651214B1 (en) | 2003-07-24 | 2009-09-16 | Warner-Lambert Company LLC | Benzimidazole derivatives as mek inhibitors |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| WO2005028426A1 (ja) | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| JP4527729B2 (ja) | 2003-12-08 | 2010-08-18 | エフ．ホフマン−ラ ロシュ アーゲー | 新規チアゾール誘導体 |
| TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| MX2007004781A (es) * | 2004-10-20 | 2007-05-11 | Applied Research Systems | Derivados de 3-arilamino piridina. |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| JP2010500994A (ja) | 2006-08-16 | 2010-01-14 | エグゼリクシス， インコーポレイテッド | Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法 |
| JP6300042B2 (ja) | 2012-10-12 | 2018-03-28 | エグゼリクシス， インコーポレイテッド | 癌の処置に使用するための化合物の製造方法 |
| KR102264639B1 (ko) | 2014-02-07 | 2021-06-11 | 스미또모 가가꾸 가부시끼가이샤 | (r)-1,1,3-트리메틸-4-아미노인단의 제조 방법 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2013
- 2013-10-14 JP JP2015536988A patent/JP6300042B2/ja active Active
- 2013-10-14 WO PCT/US2013/064866 patent/WO2014059422A1/en not_active Ceased
- 2013-10-14 SI SI201331045T patent/SI2909188T1/en unknown
- 2013-10-14 PE PE2019002024A patent/PE20191818A1/es unknown
- 2013-10-14 ES ES13780303.7T patent/ES2671502T3/es active Active
- 2013-10-14 AU AU2013328929A patent/AU2013328929B2/en active Active
- 2013-10-14 PL PL13780303T patent/PL2909188T3/pl unknown
- 2013-10-14 CN CN201810758236.XA patent/CN108948043B/zh active Active
- 2013-10-14 EP EP13780303.7A patent/EP2909188B1/en active Active
- 2013-10-14 SG SG11201502795VA patent/SG11201502795VA/en unknown
- 2013-10-14 MA MA38085A patent/MA38085B1/fr unknown
- 2013-10-14 MX MX2015004660A patent/MX372708B/es active IP Right Grant
- 2013-10-14 GE GEAP201313824A patent/GEP201706690B/en unknown
- 2013-10-14 CR CR20200237A patent/CR20200237A/es unknown
- 2013-10-14 BR BR112015008113-4A patent/BR112015008113B1/pt active IP Right Grant
- 2013-10-14 UA UAA201504532A patent/UA115455C2/uk unknown
- 2013-10-14 HK HK16101572.6A patent/HK1213567A1/zh unknown
- 2013-10-14 TR TR2018/07861T patent/TR201807861T4/tr unknown
- 2013-10-14 EA EA201590700A patent/EA030613B1/ru not_active IP Right Cessation
- 2013-10-14 NZ NZ706723A patent/NZ706723A/en unknown
- 2013-10-14 PE PE2015000485A patent/PE20151494A1/es active IP Right Grant
- 2013-10-14 IN IN3928DEN2015 patent/IN2015DN03928A/en unknown
- 2013-10-14 MY MYPI2015000897A patent/MY186549A/en unknown
- 2013-10-14 CA CA2889466A patent/CA2889466C/en active Active
- 2013-10-14 HR HRP20180670TT patent/HRP20180670T1/hr unknown
- 2013-10-14 CN CN201380064338.7A patent/CN104837826B/zh active Active
- 2013-10-14 KR KR1020157012066A patent/KR102204520B1/ko active Active
-
2015
- 2015-04-02 IL IL238116A patent/IL238116B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/02349A patent/ZA201502349B/en unknown
- 2015-04-08 PH PH12015500785A patent/PH12015500785B1/en unknown
- 2015-04-10 MX MX2020005533A patent/MX2020005533A/es unknown
- 2015-04-12 SA SA515360271A patent/SA515360271B1/ar unknown
- 2015-04-13 CL CL2015000926A patent/CL2015000926A1/es unknown
- 2015-04-13 US US14/684,826 patent/US9771347B2/en active Active
- 2015-05-11 CR CR20150245A patent/CR20150245A/es unknown
-
2017
- 2017-08-25 US US15/686,333 patent/US10239858B2/en active Active
- 2017-12-06 JP JP2017234208A patent/JP2018052973A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,215 patent/US10793541B2/en active Active
- 2019-08-08 PE PE2019001563A patent/PE20200387A1/es unknown
-
2020
- 2020-08-26 US US17/003,570 patent/US11414396B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101365676A (zh) * | 2005-10-07 | 2009-02-11 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
| CN101605540A (zh) * | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
Non-Patent Citations (2)
| Title |
|---|
| ASYMMETRIC SYNTHESIS XXVIII : HYDROXYLATED BENZOQUINOLIZIDINE ANALOGUES OF PODOPHYLLOTOXIN VIA THE CN(R,S) METHOD;Philippe Lienard et al.;《Tetrahedron》;19931231;第49卷(第19期);3995-4006 * |
| Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973);Kenneth D.Rice,et al.;《ACS Medicinal Chemistry Letters》;20120409;第3卷;416-421 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104837826B (zh) | 制备用于治疗癌症的化合物的新型方法 | |
| CN103702998A (zh) | 生产氮杂吲哚类的方法和中间体 | |
| CN108727295B (zh) | 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途 | |
| RS64654B1 (sr) | Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom | |
| CN115298199A (zh) | 环孢菌素衍生物的制备 | |
| JP7729870B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物及び組成物の製造 | |
| PT2346823E (pt) | Intermediários para a síntese de compostos 8-[{1-(3,5-bis(trifluorometil)fenil)-etóxi}-metil]-8-fenil-1,7-diazaspiro[ 4.5]decan-2-ona | |
| JP2008525486A (ja) | 置換ピペリジンの製造方法 | |
| US11739088B2 (en) | Synthesis of heterocyclic compounds | |
| JPWO2018168815A1 (ja) | ３，６−ジ置換イミダゾ［１，２−ｂ］ピリダジン誘導体の製造方法 | |
| WO2024180562A1 (en) | A process for the preparation of pure crystalline rimegepant and its salts thereof | |
| HK1213878B (en) | Novel process for making compounds for use in the treatment of cancer | |
| HK40075584A (en) | Kv3 enhancers for the treatment of cognitive disorders | |
| WO2007035003A1 (ja) | 光学活性なピペラジン化合物の製造方法 | |
| HK1256344A1 (en) | Process for producing an aminopyrrolidine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1213567 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1213567 Country of ref document: HK |